LEXIVA NEWS HIGHLIGHTS Media Articles Related to Lexiva (Fosamprenavir)
fosamprenavir-oral, Lexiva
Source: MedicineNet amprenavir Specialty [2005.03.02]
Herpes Suppression May Not Prevent HIV Infection
Source: MedicineNet Genital Herpes In Women Specialty [2008.06.20]
Complacency about HIV 'more deadly' than disease itself: IFRC (AFP)
Source: Y! Health HIV & AIDS News [2008.11.27]
Universal Testing, Prompt Treatment Could Slash HIV (HealthDay)
Source: Y! Health HIV & AIDS News [2008.11.26]
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir Vs. Lopinavir/ritonavir As Part Of HIV Combination Therapy In Treatment-Experienced Adults
Source: Conferences News From Medical News Today [2008.11.19]
Published Studies Related to Lexiva (Fosamprenavir)
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. [2007.11]
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. [2007.06.19]
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. [2006.08.05]
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. [2006.08]
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. [2006.04]
Clinical Trials Related to Lexiva (Fosamprenavir)
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects [Completed]
Fosamprenavir Expanded Access [No longer available]
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks [Completed]
Fosamprenavir Versus Other Protease Inhibitors [Completed]
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects [Terminated]
|
